Brind.

Wenyin Shi is serving as Professor of Radiation Oncology at Thomas Jefferson University, where GBM is the target of ongoing trials.

1 report, 1 independent Updated Jun 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Wenyin Shi is serving as Professor of Radiation Oncology at Thomas Jefferson University, where GBM is the target of ongoing trials.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. A Phase III clinical trial overseen by the Jefferson Brain Tumor Center failed to show benefit for early initiation, leading to market consequences for the involved companies.Sub-event
  2. Wenyin Shi appointed Professor of Radiation Oncology at Thomas Jefferson University for GBM trials.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped